Your browser doesn't support javascript.
loading
Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study.
Del Barrio-Longarela, Sara; Martínez-Taboada, Víctor M; Blanco-Olavarri, Pedro; Merino, Ana; Riancho-Zarrabeitia, Leyre; Comins-Boo, Alejandra; López-Hoyos, Marcos; Hernández, José L.
Afiliación
  • Del Barrio-Longarela S; Division of Rheumatology, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain.
  • Martínez-Taboada VM; Division of Rheumatology, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain. vmartinezt64@gmail.com.
  • Blanco-Olavarri P; University of Cantabria, Santander, Spain. vmartinezt64@gmail.com.
  • Merino A; Division of Rheumatology, Hospital Marqués de Valdecilla-IDIVAL, Santander, Spain.
  • Riancho-Zarrabeitia L; Division of Obstetrics and Ginecology, Hospital Marqués de Valdecilla, Santander, Spain.
  • Comins-Boo A; Rheumatology Department, Hospital Sierrallana-IDIVAL, Torrelavega, Spain.
  • López-Hoyos M; Immunology Department, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain.
  • Hernández JL; Immunology Department, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain.
Clin Rev Allergy Immunol ; 63(2): 297-310, 2022 Oct.
Article en En | MEDLINE | ID: mdl-34910282
The adjusted Global Antiphospholipid Syndrome (APS) Score (aGAPSS) is a tool proposed to quantify the risk for antiphospholipid antibody (aPL)-related clinical manifestations. However, aGAPSS has been validated mainly for thrombotic events and studies on APS-related obstetric manifestations are scarce. Furthermore, the majority of them included patients with positive aPL and different autoimmune diseases. Here, we assess the utility of aGAPSS to predict the response to treatment in aPL carriers without other autoimmune disorders. One-hundred and thirty-seven women with aPL ever pregnant were included. Sixty-five meet the APS classification criteria, 61 had APS-related obstetric manifestations, and 11 were asymptomatic carriers. The patients' aGAPSS risk was grouped as low (< 6, N = 73), medium (6-11, N = 40), and high risk (≥ 12, N = 24). Since vascular risk factors included in the aGAPSS were infrequent in this population (< 10%), the aGAPSS score was mainly determined by the aPL profile. Overall, the live birth rate was 75%, and 37.2% of the patients had at least one adverse pregnancy outcome (APO). When considering patients according to the aGAPSS (high, medium, and low risk), no significant differences were found for pregnancy loss (29.2%, 25%, and 21.9%) or APO (33.3%, 47.5%, and 32.9%). In the present study, including aPL carriers without other autoimmune diseases, aGAPSS is not a valuable tool to identify patients at risk for obstetric complications despite treatment. In these patients with gestational desire, in addition to the aPL profile, other pregnancy-specific factors, such as age or previous obstetric history, should be considered.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / Trombosis / Síndrome Antifosfolípido Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Pregnancy Idioma: En Revista: Clin Rev Allergy Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / Trombosis / Síndrome Antifosfolípido Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Pregnancy Idioma: En Revista: Clin Rev Allergy Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: España